No Data
No Data
Express News | Biotech Co., Ltd.: The subsidiary obtained a new veterinary drug registration certificate
Bio Co., Ltd. (600201): Non-foot-and-mouth disease products reinforce product matrix profitability and steady recovery
The 2023 and 1Q24 results are in line with our expectations, Biotech Co., Ltd. announced the 2023 and 1Q24 results: the company achieved revenue of 1,598/348 million yuan in 2023/1Q24, +4 year-on-year respectively.
Biotech Co., Ltd. (600201): Strong performance, strong performance, new products blossom, and the leader in animal insurance innovation continues to grow
The performance is resilient, and new products have blossomed more, and the leading animal insurance innovators continue to grow, maintaining the release of the 2023 annual report and the 2024 quarterly report by “buy” rating companies, with 2023 revenue of 1,598 billion yuan (+4.55%).
China Galaxy released a research report on April 25 stating that it gave Biotech Co., Ltd. (600201.SH) a recommended rating. The main reasons for the rating include: 1) the company's revenue & profit growth in 23, and steady performance in 24Q1; 2) the gr
China Galaxy released a research report on April 25 stating that it gave Biotech Co., Ltd. (600201.SH) a recommended rating. The main reasons for the rating include: 1) the company's revenue & profit growth in 23, and steady performance in 24Q1; 2) the gross margin of government harvesting increased significantly, and the growth rate of large individual pig seedlings was impressive; 3) continuous investment in research and development, and the world's first animal mRNA vaccine production workshop passed static inspection. (Mainichi Keizai Shimbun)
Bio Co., Ltd. (600201): Stable performance in 24Q1, gross margin showed an upward trend
Event: The company released its 2023 Annual Report & 2024 First Quarter Report. The company's revenue in '23 was 1,598 billion yuan, +4.55% year on year; net profit to mother was 284 million yuan, +34.64 million yuan year on year
Biotech Co., Ltd. (600201.SH) announced first-quarter results, net profit of 106 million yuan decreased by 1.05% year-on-year
Biotech Co., Ltd. (600201.SH) released its report for the first quarter of 2024. During the reporting period, the company achieved operating income of 348 million yuan, a year-on-year decrease of 4.42%; net profit attributable to shareholders of listed companies of 106 million yuan, a year-on-year decrease of 1.05%; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss of 95.32%, a year-on-year decrease of 5.32%; and basic earnings per share.
No Data